Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer (Part I Study)

Inclusion Criteria: 1. Provision of written informed consent to participate in the clinical investigation; 2. Female patient aged ≥ 18 to ≤ 75 years; 3. The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1; 4. Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan; 5. High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan. 6. The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status. 7. Patient referred for surgical treatment of breast cancer. Exclusion Criteria: 1. History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer. 2. A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator; 3. Breast inflammation/infection on the day of the probe examination; 4. Allergy to any component of the medical device that is the subject of this clinical investigation; 5. An implant in the breast where the inPROBE study and surgery will be performed; 6. Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study; 7. Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial; 8. Pregnancy or breastfeeding; 9. Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;